Clinical Trials
16 results for Prostate Cancer
UTSW SBRT Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
- Condition: Cancer Patients Receiving Stereotactic Body RTX
- Intervention: Radiation: SBRT
- Study ID: NCT02170181
Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)
- Condition: Oligometastatic Prostate Cancer
- Study ID: NCT01777802
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.
- Condition: Castration-resistant Prostate Cancer Patients With Oligometastases
- Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Drug: Triptorelin, Drug: Enzalutamide, Radiation: Stereotactic Body Radiation Therapy
- Study ID: NCT02685397
Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Definitive Prostatic Radiation and Intermittent Androgen Deprivation Therapy
- Condition: Prostatic Neoplasms
- Intervention: Drug: Pembrolizumab, Drug: SD-101, Radiation: High Dose Rate (HDR) Brachytherapy, Other: Combined Androgen Blockage (CAB)
- Study ID: NCT03007732
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- Condition: Newly Diagnosed Oligometastatic Prostate Cancer
- Intervention: Procedure: radical prostatectomy, Radiation: stereotactic body radiotherapy, Drug: Leuprolide, Drug: apalutamide, Drug: abiraterone
- Study ID: NCT03298087
PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)
- Condition: Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Cancer
- Intervention: Radiation: whole pelvic radiotherapy, Radiation: metastasis-directed treatment, Procedure: salvage Lymph Node Dissection, Drug: androgen deprivation therapy
- Study ID: NCT03569241
A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
- Condition: Prostate Cancer Metastatic to Bone
- Intervention: Drug: Radium Ra 223 Dichloride, Radiation: Radiation
- Study ID: NCT03304418
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE): A Phase II Randomized Trial
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation Therapy, Drug: Enzalutamide, Drug: Abiraterone, Drug: Docetaxel
- Study ID: NCT03556904
A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients
- Condition: Node; Prostate, Bone Metastases, Prostate Cancer Patients
- Intervention: Combination Product: SBRT + Durvalumab, Radiation: SBRT
- Study ID: NCT03795207
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
- Condition: Prostate Cancer
- Intervention: Drug: Radium-223, Radiation: stereotactic ablative radiotherapy (SABR)
- Study ID: NCT04037358
A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
- Condition: Prostate Cancer Metastatic
- Intervention: Radiation: Ablative Radiation Therapy, Other: Standard of care
- Study ID: NCT03784755
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging
- Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Intervention: Drug: Apalutamide, Radiation: Stereotactic Body Radiation Therapy
- Study ID: NCT03503344
Oligomet-DK. National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
- Condition: Prostate Cancer Metastatic
- Intervention: Procedure: RARP, Radiation: SBRT, Drug: ADT
- Study ID: NCT04086290
A Randomized, Parallel Phase II Trial of Hypofractionated Proton Beam Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic and/or Para-Aortic Lymph Nodes Following Primary Localized Treatment
- Condition: Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Intervention: Radiation: Intensity-Modulated Radiation Therapy, Radiation: Proton Beam Radiation Therapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
- Study ID: NCT04190446
Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC)
- Condition: Prostate Adenocarcinoma, PSA Level Greater Than or Equal to 0.5, PSA Level Less Than Ten
- Study ID: NCT04175431
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
- Condition: Prostate Cancer
- Study ID: NCT04302454